NatureRevClinOncol
@NatRevClinOncol
Followers
42K
Following
2K
Media
1K
Statuses
14K
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal.
London, UK
Joined August 2011
New online! Towards biomarker-driven therapies for urothelial carcinoma
nature.com
Nature Reviews Clinical Oncology - The identification of prognostic and predictive biomarkers for immune checkpoint inhibitors, antibody–drug conjugates and targeted therapies for urothelial...
0
1
4
New online! Personalized intensification of treatment for hormone-sensitive prostate cancer
nature.com
Nature Reviews Clinical Oncology - Advances in the management of hormone-sensitive prostate cancer have been achieved through intensification of therapy, although careful patient selection is...
0
2
6
New online! AI and human expertise in cancer care — striving for synergy
0
1
3
New online! Could a COVID-19 vaccine improve the effectiveness of cancer immunotherapy?
nature.com
Nature Reviews Clinical Oncology - A recent Nature article reports that mRNA vaccines against SARS-CoV-2 confer improved survival among patients with advanced-stage non-small-cell lung cancer or...
0
1
4
New online! T-DXd plus pertuzumab effective as first-line therapy
nature.com
Nature Reviews Clinical Oncology - T-DXd plus pertuzumab effective as first-line therapy
0
5
11
New online! Sentinel lymph node biopsy improves surgical management of cervical cancer
nature.com
Nature Reviews Clinical Oncology - Sentinel lymph node biopsy improves surgical management of cervical cancer
0
1
4
New online! Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
nature.com
Nature Reviews Clinical Oncology - Third-generation EGFR tyrosine kinase inhibitors such as osimertinib have substantially improved clinical outcomes in advanced-stage EGFR-mutant non-small-cell...
0
0
9
New online! The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma
nature.com
Nature Reviews Clinical Oncology - A better understanding of the development and progression of heterogeneity in oesophageal adenocarcinoma and its precursor condition, Barrett oesophagus, is...
1
3
12
New online! T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer
nature.com
Nature Reviews Clinical Oncology - T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer
0
5
12
New online! Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters
nature.com
Nature Reviews Clinical Oncology - Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters
0
0
1
New online! Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’
0
0
3
New online! From the ESMO Congress 2025
nature.com
Nature Reviews Clinical Oncology - From the ESMO Congress 2025
0
0
2
New online! Intervening on dormancy to prevent breast cancer recurrence
nature.com
Nature Reviews Clinical Oncology - Dormant tumour cells that survive initial therapy can awaken years later to seed metastases. New data from a phase II trial indicate that intercepting this...
0
0
3
New online! Domvanalimab plus zimberelimab shows promise in upper-tract cancers
nature.com
Nature Reviews Clinical Oncology - Domvanalimab plus zimberelimab shows promise in upper-tract cancers
0
0
3
New online! Perioperative therapy effective in high-risk HCC
nature.com
Nature Reviews Clinical Oncology - Perioperative therapy effective in high-risk HCC
0
2
4
New online! Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma
nature.com
Nature Reviews Clinical Oncology - Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma
0
0
2
New online! Frontline sacituzumab govitecan prolongs PFS in TNBC
nature.com
Nature Reviews Clinical Oncology - Frontline sacituzumab govitecan prolongs PFS in TNBC
0
0
3
New online! Belzutifan as a new option in pheochromocytomas and paragangliomas
nature.com
Nature Reviews Clinical Oncology - Belzutifan as a new option in pheochromocytomas and paragangliomas
0
0
1
New online! Ivonescimab delays disease progression
nature.com
Nature Reviews Clinical Oncology - Ivonescimab delays disease progression
0
0
7
New online! Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC
nature.com
Nature Reviews Clinical Oncology - Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC
0
1
3